It was recently announced that the EMA has rejected Xyrem for the treatment of fibromyalgia. Interestingly, Xyrem is already approved in Europe for the treatment of narcolepsy with cataplexy. We…
This weekend was spent attending the Natural Products ExpoWest convention in Anaheim on behalf of a few of our clients. This was our first time attending this conference. Aside from…
Drug development costs of $1 billion are often quoted. A new study estimates costs to be much lower, based on a different statistical approach.
We were intrigued by a comment made on Twitter regarding pharma employee involvement with social media: [It's] important to allow all employees to engage within guidelines and not restrict with…
This evening, @AstraZenecaUS held a fascinating Twitter chat (hashtag #RxSave). The focus of the discussion was on pharma-sponsored prescription savings plans. AZ was also looking for advice on how to…
There has been a lot of commentary this week on Pfizer's announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that…
There is a lot of good commentary and analysis of last week's JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as…
In our meetings and informal discussions, there were three items we heard again and again: 1. Last year was a terrible fund raising year from a VC-backed company perspective. 2.…
The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil,…
Earlier this week we wrote about the emerging trend of increasing state government involvement in the pharmaceutical industry. Today we learn about what the government in Brazil is doing. Of…